<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abcic</journal-id>
      <journal-title-group>
        <journal-title>ABC Imagem Cardiovascular</journal-title>
        <abbrev-journal-title abbrev-type="publisher">ABC Imagem Cardiovasc.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2318-8219</issn>
      <issn pub-type="epub">2675-312X</issn>
      <publisher>
        <publisher-name>Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiolodia (DIC/SBC)</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">pGcpq7crdxDHsgpHcBwcGwF</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S2675-312X2026000103001</article-id>
      <article-id pub-id-type="other">03001</article-id>
      <article-id pub-id-type="doi">10.36660/abcimg.20260013i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Left Ventricular Outflow Tract Velocity-Time Integral (LVOT VTI) as a Marker of Cardiac Performance: Mortality Data of the ELSA-Brasil Cohort</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-7311-4370</contrib-id>
          <name>
            <surname>Lopes</surname>
            <given-names>Mariana de Castro</given-names>
          </name>
          <role>Conception and design of the research and obtaining financing</role>
          <role>analysis and interpretation of the data and statistical analysis</role>
          <role>writing of the manuscript</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-0860-5210</contrib-id>
          <name>
            <surname>Heidemann</surname>
            <given-names>Altair Ivory</given-names>
            <suffix>Jr</suffix>
          </name>
          <role>analysis and interpretation of the data and statistical analysis</role>
          <role>critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3080-0968</contrib-id>
          <name>
            <surname>Pianca</surname>
            <given-names>Eduardo G.</given-names>
          </name>
          <role>analysis and interpretation of the data and statistical analysis</role>
          <role>critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-7491-2630</contrib-id>
          <name>
            <surname>Duncan</surname>
            <given-names>Bruce B.</given-names>
          </name>
          <role>critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2914-4406</contrib-id>
          <name>
            <surname>Foppa</surname>
            <given-names>Murilo</given-names>
          </name>
          <role>Conception and design of the research and obtaining financing</role>
          <role>analysis and interpretation of the data and statistical analysis</role>
          <role>critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2493-0547</contrib-id>
          <name>
            <surname>Santos</surname>
            <given-names>Angela B.S</given-names>
          </name>
          <role>Conception and design of the research and obtaining financing</role>
          <role>analysis and interpretation of the data and statistical analysis</role>
          <role>writing of the manuscript</role>
          <role>critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgdiv1">Cardiology Division</institution>
        <institution content-type="orgname">Hospital de Cl&#237;nicas de Porto Alegre</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Cardiology Division, Hospital de Cl&#237;nicas de Porto Alegre, Porto Alegre, RS &#8211; Brazil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgdiv2">Post-Graduate Program in Cardiology and Cardiovascular Sciences</institution>
        <institution content-type="orgdiv1">Medical School</institution>
        <institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS &#8211; Brazil</institution>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution content-type="orgdiv2">Post-Graduate Program in Epidemiology</institution>
        <institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Post-Graduate Program in Epidemiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS &#8211; Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"><label>Mailing Address:</label> Mariana de Castro Lopes &#8226; Hospital de Cl&#237;nicas de Porto Alegre. Rua Ramiro Barcelos, 2350, Sala 2061. Postal code: 90035-903. Porto Alegre, RS &#8211; Brazil. Email: marianadecastro.lopes@gmail.com </corresp>
        <fn fn-type="edited-by">
          <label>Editor responsible for the review:</label>
          <p>Marcelo Tavares</p>
        </fn>
        <fn fn-type="coi-statement">
          <label>Potential Conflict of Interest:</label>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>17</day>
        <month>04</month>
        <year>2026</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2026</year>
      </pub-date>
      <volume>39</volume>
      <issue>1</issue>
      <elocation-id>e20260013</elocation-id>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>02</month>
          <year>2026</year>
        </date>
        <date date-type="rev-recd">
          <day>09</day>
          <month>02</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>02</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Echocardiography</kwd>
        <kwd>Risk Assessment</kwd>
        <kwd>Mortality</kwd>
        <kwd>Healthy Volunteers</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement><bold>Sources of Funding:</bold> There were no external funding sources for this study.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="4"/>
        <equation-count count="0"/>
        <ref-count count="7"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>Transthoracic Echocardiography (TTE) is a well-established tool for assessing cardiac function and hemodynamics. While Left Ventricular (LV) systolic and diastolic function are commonly used metrics, Cardiac Output (CO) remains central for evaluating hemodynamic status, especially in critical care settings. TTE-derived parameters, such as Left Ventricular Outflow Tract Velocity-Time Integral (LVOT VTI) and LVOT area, when combined with body habitus and heart rate, provide noninvasive estimates of cardiac output. However, the accuracy of CO calculations may decrease when multiple covariates are included, with LVOT diameter being a major source of error.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> In contrast, isolated LVOT VTI may represent a simpler and more reliable surrogate of cardiac performance.</p>
    <p>Among patients with Heart Failure with reduced Ejection Fraction (HFrEF), LVOT VTI values below 12 cm or 8 cm have been associated with worse cardiovascular outcomes, with a progressive increase in risk as VTI decreases.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> Similarly, in intermediate to high-risk pulmonary embolism, LVOT VTI &#8804; 15 cm has been associated with higher in-hospital mortality, cardiopulmonary arrest, shock, and need for reperfusion therapy.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> In secondary mitral regurgitation, LVOT VTI &#8804; 17 cm predicts both cardiovascular and all-cause mortality.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> And in ambulatory adults with stable Coronary Artery Disease (CAD), LVOT VTI &#8804; 18 cm was associated with heart failure hospitalization and mortality.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Despite these findings, there is limited data to evaluate the usefulness of LVOT VTI in free-dwelling adults.</p>
    <p>In this study, we aimed to identify the association between LVOT VTI and mortality among participants in the ELSA-Brasil cohort, a multicenter occupational study of Brazilian adults.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Participants underwent standardized TTE between 2008 and 2010 based on published guidelines. All these exams were subsequently analyzed in a core lab.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Measurements included LVOT VTI, LV Ejection Fraction (LVEF), Stroke Volume Index (SVI), and Cardiac Index (CI). Mortality was assessed through annual follow-up and adjudicated by the investigators up to December 2022.</p>
    <p>Echocardiographic data were available for 2,237 participants (58.6 &#177; 9.1 years, 46% male). The mean of LVOT VTI was 19.6 &#177; 4.0 cm, and 111% had a value of LVOT VTI below the pre-specified cutoff (&lt; 15 cm), a value similar to the other studies&#8217; cutoff and positioned between the 10<sup>th</sup> and 25<sup>th</sup> percentiles of our sample distribution. Participants with LVOT VTI &lt; 15 cm were slightly older (57 &#177; 9.9 vs 58.8 &#177; 8.9, p = 0.009) and showed a higher proportion of males (63% vs 44%, p &lt; 0.001) than the LVOT VTI &#8805; 15 cm group. The prevalence of other parameters of cardiac performance below established abnormality thresholds<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> was as follows: LVEF &lt; 50% (N = 71, 3%), SVI &lt; 38 mL/m<sup>2</sup> (N = 1673, 74%), and CI &#8804; 2 L/min/m<sup>2</sup> (N = 905, 40%). The distribution of other relevant variables is depicted in <italic><xref ref-type="table" rid="t1">Table 1</xref></italic>. Over a mean follow-up period of 11.8 &#177; 2.2 years, 199 (8.9%) participants died (137 males and 62 females).</p>
    <p>
      <table-wrap id="t1">
        <label>Table 1</label>
        <caption>
          <title>Baseline characteristics.</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="20%">
            <col/>
            <col/>
            <col/>
            <col/>
            <col/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" style="font-weight:normal"> </th>
              <th style="font-weight:normal">Overall N = 2,237</th>
              <th style="font-weight:normal">LVOT VTI &lt; 15 cm N = 246</th>
              <th style="font-weight:normal">LVOT VTI &#8805; 15 cm N = 1,991</th>
              <th style="font-weight:normal">p-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Male Sex (%)</td>
              <td align="center">1028 (46)</td>
              <td align="center">157 (64)</td>
              <td align="center">871 (44)</td>
              <td align="center">&lt; 0.001</td>
            </tr>
            <tr>
              <td>Age (years)</td>
              <td align="center">58.6 &#177; 9</td>
              <td align="center">57 &#177; 9.9</td>
              <td align="center">58.8 &#177; 8.9</td>
              <td align="center">0.009</td>
            </tr>
            <tr>
              <td>Heart rate (bpm)</td>
              <td align="center">67 &#177; 10</td>
              <td align="center">73.9 &#177; 11.6</td>
              <td align="center">66.7 &#177; 10.1</td>
              <td align="center">&lt; 0.001</td>
            </tr>
            <tr>
              <td>SBP</td>
              <td align="center">125.1 &#177; 18.8</td>
              <td align="center">126.1 &#177; 18.3</td>
              <td align="center">125 &#177; 18.8</td>
              <td align="center">0.38</td>
            </tr>
            <tr>
              <td>DBP</td>
              <td align="center">76.1 &#177; 10.7</td>
              <td align="center">78.8 &#177; 11.1</td>
              <td align="center">75.8 &#177; 10.7</td>
              <td align="center">&lt; 0.001</td>
            </tr>
            <tr>
              <td>Height (cm)</td>
              <td align="center">163.9 &#177; 9.3</td>
              <td align="center">165.9 &#177; 9.7</td>
              <td align="center">163.7 &#177; 9.3</td>
              <td align="center">&lt; 0.001</td>
            </tr>
            <tr>
              <td>Weight (kg)</td>
              <td align="center">72 &#177; 13.5</td>
              <td align="center">72.4 &#177; 13.6</td>
              <td align="center">71.9 &#177; 13.6</td>
              <td align="center">0.57</td>
            </tr>
            <tr>
              <td>Body surface area (m&#178;)</td>
              <td align="center">1.77 &#177; 0.19</td>
              <td align="center">1.79 &#177; 0.2</td>
              <td align="center">1.77 &#177; -0.19</td>
              <td align="center">0.073</td>
            </tr>
            <tr>
              <td>Body mass index (kg/m&#178;)</td>
              <td align="center">26.5 &#177; 4.2</td>
              <td align="center">25.9 &#177; 3.55</td>
              <td align="center">26.6 &#177; 4.12</td>
              <td align="center">0.11</td>
            </tr>
            <tr>
              <td>Hypertension (%)</td>
              <td align="center">1019 (45.6)</td>
              <td align="center">119 (48)</td>
              <td align="center">900 (45)</td>
              <td align="center">0.364</td>
            </tr>
            <tr>
              <td>Diabetes (%)</td>
              <td align="center">459 (20.5)</td>
              <td align="center">53 (21)</td>
              <td align="center">406 (20)</td>
              <td align="center">0.675</td>
            </tr>
            <tr>
              <td>LVEF (%)</td>
              <td align="center">66 &#177; 8.2</td>
              <td align="center">60.5 &#177; 11.7</td>
              <td align="center">67.1 &#177; 7.3</td>
              <td align="center">&lt;0.001</td>
            </tr>
            <tr>
              <td>SV index (mL/m&#178;)</td>
              <td align="center">32.8 &#177; 8.7</td>
              <td align="center">25.3 &#177; 5.9</td>
              <td align="center">33.8 &#177; 8.5</td>
              <td align="center">&lt;0.001</td>
            </tr>
            <tr>
              <td>Cardiac output (L/min)</td>
              <td align="center">3.89 &#177; 1.1</td>
              <td align="center">3.3 &#177; 0.98</td>
              <td align="center">3.9 &#177; 1.1</td>
              <td align="center">&lt;0.001</td>
            </tr>
            <tr>
              <td>Cardiac index (L/min/m&#178;)</td>
              <td align="center">2.19 &#177; 0.58</td>
              <td align="center">1.8 &#177; 0.5</td>
              <td align="center">2.2 &#177; 0.59</td>
              <td align="center">&lt;0.001</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <p>Continuous variables are expressed as mean &#177; SD and categorical variables as number (percentage). SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; SV: Stroke Volume, LVEF: Left Ventricular Ejection Fraction.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </p>
    <p>Mortality was higher among participants with an LVOT-VTI &lt; 15 cm compared with those with higher values (12.6% vs. 8.4%; log-rank test &#967;&#178; = 4.68, p = 0.026; <italic><xref ref-type="fig" rid="f01">Figure 1</xref></italic>). The multivariable Cox proportional hazards analysis showed that this association was independent of age and sex (Model 1- HR 1.48; 95% CI 1.00&#8211;2.18; <italic>p</italic> = 0.048). Additionally, this association remained significant after adjustment for body surface area (Model 2), slightly attenuated after adjustment for systolic blood pressure (Model 3- HR 1.46; 95% CI 0.99&#8211;2.15; <italic>p</italic> = 0.053) (<italic><xref ref-type="table" rid="t2">Table 2</xref></italic>). Overall, lower LVOT-VTI was consistently associated with an increased risk of mortality across all models, even after sequential adjustment for demographic and hemodynamic covariates.</p>
    <p>
      <fig id="f01">
        <label>Figure 1</label>
        <caption>
          <title>Kaplan-Meier survival according to LVOT VTI category (&lt; 15 cm vs. &#8805; 15 cm).</title>
        </caption>
        <graphic xlink:href="2675-312X-abcic-39-01-e20260013-0013i-gf01.tif"/></fig>
    </p>
    <p>
      <table-wrap id="t2">
        <label>Table 2</label>
        <caption>
          <title>Multivariable Cox proportional hazards models for all-cause mortality according to LVOT-VTI (&lt; 15 cm vs. &#8805; 15 cm)</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="25%">
            <col/>
            <col/>
            <col/>
            <col/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" style="font-weight:normal"> </th>
              <th style="font-weight:normal">Model 1</th>
              <th style="font-weight:normal">Model 2</th>
              <th style="font-weight:normal">Model 3</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td> </td>
              <td align="center"> </td>
              <td align="center">HR (95% IC), p-value</td>
              <td align="center"> </td>
            </tr>
            <tr>
              <td>Age (years)</td>
              <td align="center">1.09 (1.07&#8211;1.12), p &lt; 0.001</td>
              <td align="center">1.09 (1.07&#8211;1.12), p &lt; 0.001</td>
              <td align="center">1.08 (1.06&#8211;1.11), p &lt; 0.001</td>
            </tr>
            <tr>
              <td>Male sex</td>
              <td align="center">2.58 (1.91&#8211;3.50), p &lt; 0.001</td>
              <td align="center">2.70 (1.90&#8211;3.84), p &lt; 0.001</td>
              <td align="center">2.47 (1.74&#8211;3.52), p &lt; 0.001</td>
            </tr>
            <tr>
              <td>LVOT-VTI &lt; 15 cm</td>
              <td align="center">1.48 (CI 1.00&#8211;2.18), p = 0.048</td>
              <td align="center">1.48 (1.00&#8211;2.17), p = 0.048</td>
              <td align="center">1.46 (0.99&#8211;2.15), p = 0.053</td>
            </tr>
            <tr>
              <td>BSA (m&#178;)</td>
              <td align="center">&#8212;</td>
              <td align="center">0.81 (0.34&#8211;1.92), p = 0.637</td>
              <td align="center">0.83 (0.35&#8211;1.98), p = 0.682</td>
            </tr>
            <tr>
              <td>SBP (mmHg)</td>
              <td align="center">&#8212;</td>
              <td align="center">&#8212;</td>
              <td align="center">1.01 (1.01&#8211;1.02), p &lt; 0.001</td>
            </tr>
            <tr>
              <td>p (overall model)</td>
              <td align="center">&lt; 0.001</td>
              <td align="center">&lt; 0.001</td>
              <td align="center">&lt; 0.001</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN2">
            <p>LVOT-VTI: left ventricular outflow tract velocity&#8211;time integral; BSA: body surface area; SBP: systolic blood pressure; HR: hazard ratio; CI: confidence interval.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </p>
    <p>Additionally, LVOT VI showed a weak correlation with height (r = -0.073; p &lt; 0.001), and no significant correlation with weight (r = 0.039; p = 0.067), or with BSA (r = 0.0003, p = 0.99), reinforcing the independence of LVOT TVI with body habitus.</p>
    <p>In summary, LVOT VTI &lt;15 cm was associated with a higher mortality among community-dwelling adults in this middle-income country. LVOT VTI may serve as a simple screening metric for cardiac performance in cardiovascular risk stratification of general populations, independently of adjustment for demographic and hemodynamic covariates. Further research is warranted to confirm the independent role of LVOT VTI in risk classification and to define relevant thresholds in specific settings.</p>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Goldman JH, Schiller NB, Lim DC, Redberg RF, Foster E. Usefulness of Stroke Distance by Echocardiography as a Surrogate Marker of Cardiac Output that is Independent of Gender and Size in a Normal Population. Am J Cardiol. 2001;87(4):499-502. doi: 10.1016/s0002-9149(00)01417-x.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldman</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Redberg</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Usefulness of Stroke Distance by Echocardiography as a Surrogate Marker of Cardiac Output that is Independent of Gender and Size in a Normal Population</article-title>
          <source>Am J Cardiol</source>
          <year>2001</year>
          <volume>87</volume>
          <issue>4</issue>
          <fpage>499</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="doi">10.1016/s0002-9149(00)01417-x</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Dini FL, Barletta V, Ballo P, Cioffi G, Pugliese NR, Rossi A, et al. Left Ventricular Outflow Indices in Chronic Systolic Heart Failure: Thresholds and Prognostic Value. Echocardiography. 2025;42(2):e70109. doi: 10.1111/echo.70109.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dini</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Barletta</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ballo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cioffi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pugliese</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Left Ventricular Outflow Indices in Chronic Systolic Heart Failure: Thresholds and Prognostic Value</article-title>
          <source>Echocardiography</source>
          <year>2025</year>
          <volume>42</volume>
          <issue>2</issue>
          <elocation-id>e70109</elocation-id>
          <pub-id pub-id-type="doi">10.1111/echo.70109</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Tan C, Rubenson D, Srivastava A, Mohan R, Smith MR, Billick K, et al. Left Ventricular Outflow Tract Velocity Time Integral Outperforms Ejection Fraction and Doppler-Derived Cardiac Output for Predicting Outcomes in a Select Advanced Heart Failure Cohort. Cardiovasc Ultrasound. 2017;15(1):18. doi: 10.1186/s12947-017-0109-4.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rubenson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Srivastava</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mohan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Billick</surname>
              <given-names>K</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Left Ventricular Outflow Tract Velocity Time Integral Outperforms Ejection Fraction and Doppler-Derived Cardiac Output for Predicting Outcomes in a Select Advanced Heart Failure Cohort</article-title>
          <source>Cardiovasc Ultrasound</source>
          <year>2017</year>
          <volume>15</volume>
          <issue>1</issue>
          <size units="pages">18</size>
          <pub-id pub-id-type="doi">10.1186/s12947-017-0109-4</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Yurtdisik E, Mitchell OI, Sibley RA, Xia Y, Sista AK, Zhong J, et al. Low Left Ventricular Outflow Tract Velocity Time Integral is Associated with Poor Outcomes in Acute Pulmonary Embolism. Vasc Med. 2020;25(2):133-40. doi: 10.1177/1358863X19880268.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yurtdisik</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>OI</given-names>
            </name>
            <name>
              <surname>Sibley</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sista</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Low Left Ventricular Outflow Tract Velocity Time Integral is Associated with Poor Outcomes in Acute Pulmonary Embolism</article-title>
          <source>Vasc Med</source>
          <year>2020</year>
          <volume>25</volume>
          <issue>2</issue>
          <fpage>133</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="doi">10.1177/1358863X19880268</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Gentile F, Buoncristiani F, Sciarrone P, Bazan L, Panichella G, Gasparini S, et al. Left Ventricular Outflow Tract Velocity-Time Integral Improves Outcome Prediction in Patients with Secondary Mitral Regurgitation. Int J Cardiol. 2023;392:131272. doi: 10.1016/j.ijcard.2023.131272.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gentile</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Buoncristiani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sciarrone</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bazan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Panichella</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gasparini</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Left Ventricular Outflow Tract Velocity-Time Integral Improves Outcome Prediction in Patients with Secondary Mitral Regurgitation</article-title>
          <source>Int J Cardiol</source>
          <year>2023</year>
          <volume>392</volume>
          <size units="pages">131272</size>
          <pub-id pub-id-type="doi">10.1016/j.ijcard.2023.131272</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Ristow B, Na B, Ali S, Whooley MA, Schiller NB. Left Ventricular Outflow Tract and Pulmonary Artery Stroke Distances Independently Predict Heart Failure Hospitalization and Mortality: The Heart and Soul Study. J Am Soc Echocardiogr. 2011;24(5):565-72. doi: 10.1016/j.echo.2010.12.024.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ristow</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Na</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Whooley</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
          </person-group>
          <article-title>Left Ventricular Outflow Tract and Pulmonary Artery Stroke Distances Independently Predict Heart Failure Hospitalization and Mortality: The Heart and Soul Study</article-title>
          <source>J Am Soc Echocardiogr</source>
          <year>2011</year>
          <volume>24</volume>
          <issue>5</issue>
          <fpage>565</fpage>
          <lpage>572</lpage>
          <pub-id pub-id-type="doi">10.1016/j.echo.2010.12.024</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Mill JG, Pinto K, Griep RH, Goulart A, Foppa M, Lotufo PA, et al. Medical Assessments and Measurements in ELSA-Brasil. Rev Saude Publica. 2013;47 (Suppl 2):54-62. doi: 10.1590/s0034-8910.2013047003851.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mill</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Pinto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Griep</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Goulart</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Foppa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lotufo</surname>
              <given-names>PA</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Medical Assessments and Measurements in ELSA-Brasil</article-title>
          <source>Rev Saude Publica</source>
          <year>2013</year>
          <volume>47</volume>
          <supplement>Suppl 2</supplement>
          <fpage>54</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1590/s0034-8910.2013047003851</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <label>Study Association:</label>
        <p> This study is not associated with any thesis or dissertation work.</p>
      </fn>
      <fn fn-type="other">
        <label>Ethics Approval and Consent to Participate:</label>
        <p> This study was approved by the Ethics Committee of the Hospital Cl&#237;nicas de Porto Alegre under the protocol number 0017.1.069.000-06 194/06. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p>
      </fn>
      <fn fn-type="other">
        <label>Use of Artificial Intelligence:</label>
        <p> The authors did not use any artificial intelligence tools in the development of this work.</p>
      </fn>
      <fn fn-type="data-availability" specific-use="data-available-upon-request">
        <label>Availability of Research Data:</label>
        <p> All datasets supporting the results of this study are available upon request from the corresponding author.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <label>Sources of Funding:</label>
        <p> There were no external funding sources for this study.</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRpt" xml:lang="pt">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abcimg.20260013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Comunica&#231;&#227;o Breve</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Integral Velocidade&#8211;Tempo do Trato de Sa&#237;da do Ventr&#237;culo Esquerdo (LVOT VTI) Como Marcador de Desempenho Card&#237;aco: Dados de Mortalidade da Coorte ELSA-Brasil</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-7311-4370</contrib-id>
          <name>
            <surname>Lopes</surname>
            <given-names>Mariana de Castro</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>obten&#231;&#227;o de dados</role>
          <role>an&#225;lise e interpreta&#231;&#227;o dos dados e an&#225;lise estat&#237;stica</role>
          <role>reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-0860-5210</contrib-id>
          <name>
            <surname>Heidemann</surname>
            <given-names>Altair Ivory</given-names>
            <suffix>Jr</suffix>
          </name>
          <role>an&#225;lise e interpreta&#231;&#227;o dos dados e an&#225;lise estat&#237;stica</role>
          <role>revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3080-0968</contrib-id>
          <name>
            <surname>Pianca</surname>
            <given-names>Eduardo G.</given-names>
          </name>
          <role>an&#225;lise e interpreta&#231;&#227;o dos dados e an&#225;lise estat&#237;stica</role>
          <role>revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-7491-2630</contrib-id>
          <name>
            <surname>Duncan</surname>
            <given-names>Bruce B.</given-names>
          </name>
          <role>revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff2002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3002">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2914-4406</contrib-id>
          <name>
            <surname>Foppa</surname>
            <given-names>Murilo</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>obten&#231;&#227;o de dados</role>
          <role>an&#225;lise e interpreta&#231;&#227;o dos dados e an&#225;lise estat&#237;stica</role>
          <role>revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2493-0547</contrib-id>
          <name>
            <surname>Santos</surname>
            <given-names>Angela B.S</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>obten&#231;&#227;o de dados</role>
          <role>an&#225;lise e interpreta&#231;&#227;o dos dados e an&#225;lise estat&#237;stica</role>
          <role>reda&#231;&#227;o do manuscrito</role>
          <role>revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2002">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1002">
        <label>1</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Cardiology Division, Hospital de Cl&#237;nicas de Porto Alegre, Porto Alegre, RS &#8211; Brasil</institution>
      </aff>
      <aff id="aff2002">
        <label>2</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS &#8211; Brasil</institution>
      </aff>
      <aff id="aff3002">
        <label>3</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Post-Graduate Program in Epidemiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01002"><label>Correspond&#234;ncia:</label> Mariana de Castro Lopes Hospital de Clinicas de Porto Alegre. Rua Ramiro Barcelos, 2350, Sala 2061. CEP: 90035-903. Porto Alegre, RS &#8211; Brasil. Email: marianadecastro.lopes@gmail.com </corresp>
        <fn fn-type="edited-by">
          <label>Editor respons&#225;vel pela revis&#227;o:</label>
          <p>Marcelo Tavares</p>
        </fn>
        <fn fn-type="coi-statement">
          <label>Potencial Conflito de Interesse:</label>
          <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
        </fn>
      </author-notes>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Ecocardiografia</kwd>
        <kwd>Medi&#231;&#227;o de Risco</kwd>
        <kwd>Mortalidade</kwd>
        <kwd>Volunt&#225;rios Saud&#225;veis</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement><bold>Fontes de Financiamento:</bold> O presente estudo n&#227;o teve fontes de financiamento externas.</funding-statement>
      </funding-group>
    </front-stub>
    <body>
      <p>A Ecocardiografia Transtor&#225;cica (ETT) &#233; uma ferramenta amplamente estabelecida para a avalia&#231;&#227;o da fun&#231;&#227;o card&#237;aca e da hemodin&#226;mica. Embora par&#226;metros de fun&#231;&#227;o sist&#243;lica e diast&#243;lica do Ventr&#237;culo Esquerdo (VE) sejam comumente utilizados, o D&#233;bito Card&#237;aco (DC) permanece central na avalia&#231;&#227;o do estado hemodin&#226;mico, especialmente em contextos de cuidados intensivos. Par&#226;metros derivados da ETT, como a Integral Velocidade&#8211;Tempo do Trato de Sa&#237;da do Ventr&#237;culo Esquerdo (LVOT VTI) e a &#225;rea do trato de sa&#237;da, quando combinados a caracter&#237;sticas antropom&#233;tricas e &#224; frequ&#234;ncia card&#237;aca, permitem estimativas n&#227;o invasivas do d&#233;bito card&#237;aco. Entretanto, a precis&#227;o dos c&#225;lculos de DC pode diminuir quando m&#250;ltiplas covari&#225;veis s&#227;o inclu&#237;das, sendo o di&#226;metro da LVOT uma das principais fontes de erro.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Em contraste, a LVOT VTI isoladamente pode representar um marcador substituto mais simples e potencialmente mais reprodut&#237;vel do desempenho card&#237;aco.</p>
      <p>Em pacientes com Insufici&#234;ncia Card&#237;aca com Fra&#231;&#227;o de Eje&#231;&#227;o reduzida (ICFEr), valores de LVOT VTI inferiores a 12 cm ou 8 cm foram associados a piores desfechos cardiovasculares, com aumento progressivo do risco &#224; medida que o VTI diminui.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> De forma semelhante, em casos de embolia pulmonar de risco intermedi&#225;rio a alto, uma LVOT VTI &#8804; 15 cm associou-se a maior mortalidade intra-hospitalar, parada cardiorrespirat&#243;ria, choque e necessidade de terapia de reperfus&#227;o.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Na insufici&#234;ncia mitral secund&#225;ria, uma LVOT VTI &#8804; 17 cm prediz mortalidade cardiovascular mortalidade por todas as causas.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Em adultos ambulatoriais com Doen&#231;a Arterial Coronariana (DAC) est&#225;vel, LVOT VTI &#8804; 18 cm esteve associado &#224; hospitaliza&#231;&#227;o por insufici&#234;ncia card&#237;aca e &#224; mortalidade.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Apesar desses achados, ainda h&#225; dados limitados quanto &#224; utilidade da LVOT VTI em adultos vivendo na comunidade.</p>
      <p>Neste estudo, buscamos avaliar a associa&#231;&#227;o entre LVOT VTI e mortalidade entre participantes da coorte ELSA-Brasil, um estudo multic&#234;ntrico ocupacional com adultos brasileiros.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Os participantes foram submetidos &#224; ETT padronizada entre 2008 e 2010, conforme diretrizes publicadas. Todos os exames foram posteriormente analisados em laborat&#243;rio central.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> As medidas inclu&#237;ram LVOT VTI, Fra&#231;&#227;o de Eje&#231;&#227;o do Ventr&#237;culo Esquerdo (FEVE), &#205;ndice de Volume Sist&#243;lico (IVS) e &#205;ndice Card&#237;aco (IC). A mortalidade foi avaliada por acompanhamento anual e adjudicada pelos investigadores at&#233; dezembro de 2022.</p>
      <p>Dados ecocardiogr&#225;ficos estavam dispon&#237;veis para 2.237 participantes (58,6 &#177; 9,1 anos; 46% do sexo masculino). A m&#233;dia da LVOT VTI foi 19,6 &#177; 4,0 cm, e 11% apresentaram valor inferior ao ponto de corte pr&#233;-especificado (&lt; 15 cm), semelhante aos pontos de corte adotados em outros estudos e situado entre os percentis 10 e 25 da distribui&#231;&#227;o da amostra. Participantes com LVOT VTI &lt; 15 cm eram ligeiramente mais velhos (57 &#177; 9,9 vs. 58,8 &#177; 8,9 anos; p = 0,009) e apresentavam maior propor&#231;&#227;o de homens (63% vs. 44%; p &lt; 0,001) em compara&#231;&#227;o ao grupo com LVOT VTI &#8805; 15 cm. A preval&#234;ncia de outros par&#226;metros de desempenho card&#237;aco abaixo dos limiares estabelecidos de anormalidade<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> foi: FEVE &lt; 50% (n = 71; 3%), IVS &#8804; 38 mL/m&#178; (n = 1.673; 74%) e IC &#8804; 2 L/min/m&#178; (n = 905; 40%). A distribui&#231;&#227;o das demais vari&#225;veis relevantes encontra-se na <xref ref-type="table" rid="t1002">Tabela 1</xref>. Durante acompanhamento m&#233;dio de 11,8 &#177; 2,2 anos, ocorreram 199 &#243;bitos (8,9%), sendo 137 em homens e 62 em mulheres.</p>
      <p>
        <table-wrap id="t1002">
          <label>Tabela 1</label>
          <caption>
            <title>&#8211; Caracter&#237;sticas basais.</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" style="font-weight:normal"> </th>
                <th style="font-weight:normal">Geral (N = 2.237)</th>
                <th style="font-weight:normal">LVOT VTI &lt; 15 cm N = 246</th>
                <th style="font-weight:normal">LVOT VTI &#8805; 15 cm N = 1.991</th>
                <th style="font-weight:normal">Valor de p</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Sexo masculino (%)</td>
                <td align="center">1028 (46)</td>
                <td align="center">157 (64)</td>
                <td align="center">871 (44)</td>
                <td align="center">&lt; 0,001</td>
              </tr>
              <tr>
                <td>Idade (anos)</td>
                <td align="center">58,6 &#177; 9</td>
                <td align="center">57 &#177; 9,9</td>
                <td align="center">58,8 &#177; 8,9</td>
                <td align="center">0,009</td>
              </tr>
              <tr>
                <td>Frequ&#234;ncia card&#237;aca (bpm)</td>
                <td align="center">67 &#177; 10</td>
                <td align="center">73,9 &#177; 11,6</td>
                <td align="center">66,7 &#177; 10,1</td>
                <td align="center">&lt; 0,001</td>
              </tr>
              <tr>
                <td>PAS</td>
                <td align="center">125,1 &#177; 18,8</td>
                <td align="center">126,1 &#177; 18,3</td>
                <td align="center">125 &#177; 18,8</td>
                <td align="center">0,38</td>
              </tr>
              <tr>
                <td>PAD</td>
                <td align="center">76,1 &#177; 10,7</td>
                <td align="center">78,8 &#177; 11,1</td>
                <td align="center">75,8 &#177; 10,7</td>
                <td align="center">&lt; 0,001</td>
              </tr>
              <tr>
                <td>Altura (cm)</td>
                <td align="center">163,9 &#177; 9,3</td>
                <td align="center">165,9 &#177; 9,7</td>
                <td align="center">163,7 &#177; 9,3</td>
                <td align="center">&lt; 0,001</td>
              </tr>
              <tr>
                <td>Peso (kg)</td>
                <td align="center">72 &#177; 13,5</td>
                <td align="center">72,4 &#177; 13,6</td>
                <td align="center">71,9 &#177; 13,6</td>
                <td align="center">0,57</td>
              </tr>
              <tr>
                <td>&#193;rea de superf&#237;cie corporal (m&#178;)</td>
                <td align="center">1,77 &#177; 0,19</td>
                <td align="center">1,79 &#177; 0,2</td>
                <td align="center">1,77 &#177; -0,19</td>
                <td align="center">0,073</td>
              </tr>
              <tr>
                <td>&#205;ndice de massa corporal kg/m&#178;)</td>
                <td align="center">26,5 &#177; 4,2</td>
                <td align="center">25,9 &#177; 3,55</td>
                <td align="center">26,6 &#177; 4,12</td>
                <td align="center">0,11</td>
              </tr>
              <tr>
                <td>Hipertens&#227;o, (%)</td>
                <td align="center">1019 (45,6)</td>
                <td align="center">119 (48)</td>
                <td align="center">900 (45)</td>
                <td align="center">0,364</td>
              </tr>
              <tr>
                <td>Diabetes (%)</td>
                <td align="center">459 (20,5)</td>
                <td align="center">53 (21)</td>
                <td align="center">406 (20)</td>
                <td align="center">0,675</td>
              </tr>
              <tr>
                <td>FEVE (%)</td>
                <td align="center">66 &#177; 8,2</td>
                <td align="center">60,5 &#177; 11,7</td>
                <td align="center">67,1 &#177; 7,3</td>
                <td align="center">&lt; 0,001</td>
              </tr>
              <tr>
                <td>&#205;ndice de SV (mL/m&#178;)</td>
                <td align="center">32,8 &#177; 8,7</td>
                <td align="center">25,3 &#177; 5,9</td>
                <td align="center">33,8 &#177; 8,5</td>
                <td align="center">&lt; 0,001</td>
              </tr>
              <tr>
                <td>D&#233;bito card&#237;aco (L/min)</td>
                <td align="center">3,89 &#177; 1,1</td>
                <td align="center">3,3 &#177; 0,98</td>
                <td align="center">3,9 &#177; 1,1</td>
                <td align="center">&lt; 0,001</td>
              </tr>
              <tr>
                <td>&#205;ndice card&#237;aco (L/min&#178;)</td>
                <td align="center">2,19 &#177; 0,58</td>
                <td align="center">1,8 &#177; 0,5</td>
                <td align="center">2,2 &#177; 0,59</td>
                <td align="center">&lt; 0,001</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN1002">
              <p>As vari&#225;veis cont&#237;nuas s&#227;o expressas como m&#233;dia &#177; desvio padr&#227;o e as vari&#225;veis categ&#243;ricas como n&#250;mero (percentagem). PAS: Press&#227;o Arterial Sist&#243;lica; PAD: Press&#227;o Arterial Diast&#243;lica; VS: Volume sist&#243;lico, FEVE: Fra&#231;&#227;o de Eje&#231;&#227;o do Ventr&#237;culo Esquerdo.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>A mortalidade foi maior entre os participantes com LVOT VTI &lt; 15 cm em compara&#231;&#227;o &#224;queles com valores &#8805; 15 cm (12,6% vs. 8,4%; teste de log-rank &#967;&#178; = 4,68; p = 0,026; <xref ref-type="fig" rid="f01002">Figura 1</xref>). Na an&#225;lise multivariada por modelo de riscos proporcionais de Cox, essa associa&#231;&#227;o mostrou-se independente de idade e sexo (Modelo 1: HR 1,48; IC de 95% 1,00&#8211;2,18; p = 0,048). A associa&#231;&#227;o permaneceu significativa ap&#243;s ajuste para &#225;rea de superf&#237;cie corporal (Modelo 2) e apresentou discreta atenua&#231;&#227;o ap&#243;s ajuste adicional para press&#227;o arterial sist&#243;lica (Modelo 3: HR 1,46; IC de 95% 0,99&#8211;2,15; p = 0,053) (<xref ref-type="table" rid="t2002">Tabela 2</xref>). De modo geral, valores mais baixos de LVOT VTI associaram-se de forma consistente a maior risco de mortalidade em todos os modelos, mesmo ap&#243;s ajustes sequenciais para covari&#225;veis demogr&#225;ficas e hemodin&#226;micas.</p>
      <p>
        <fig id="f01002">
          <label>Figura 1</label>
          <caption>
            <title>&#8211; Sobrevida de Kaplan-Meier de acordo com a categoria VTI da LVOT (&lt; 15 cm vs. &#8805; 15 cm).</title>
          </caption>
          <graphic xlink:href="2675-312X-abcic-39-01-e20260013-0013i-gf01-pt.tif"/></fig>
      </p>
      <p>
        <table-wrap id="t2002">
          <label>Tabela 2</label>
          <caption>
            <title>&#8211; Modelos multivariados de Cox para mortalidade por todas as causas segundo LVOT VTI (&lt; 15 cm vs. &#8805; 15 cm)</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" style="font-weight:normal"> </th>
                <th style="font-weight:normal">Modelo 1</th>
                <th style="font-weight:normal">Modelo 2</th>
                <th style="font-weight:normal">Modelo 3</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td> </td>
                <td align="center"> </td>
                <td align="center">HR (IC de 95%) - Valor de p</td>
                <td align="center"> </td>
              </tr>
              <tr>
                <td>Idade (anos)</td>
                <td align="center">1,09 (1,07&#8211;1,12), <italic>p</italic> &lt; 0,001</td>
                <td align="center">1,09 (1,07&#8211;1,12), <italic>p</italic> &lt; 0,001</td>
                <td align="center">1,08 (1,06&#8211;1,11), <italic>p</italic> &lt; 0,001</td>
              </tr>
              <tr>
                <td>Sexo masculino</td>
                <td align="center">2,58 (1,91&#8211;3,50), <italic>p</italic> &lt; 0,001</td>
                <td align="center">2,70 (1,90&#8211;3,84), <italic>p</italic> &lt; 0,001</td>
                <td align="center">2,47 (1,74&#8211;3,52), <italic>p</italic> &lt; 0,001</td>
              </tr>
              <tr>
                <td>LVOT-VTI &lt; 15 cm</td>
                <td align="center">1,48 (1.00&#8211;2.18), <italic>p</italic> = 0,048</td>
                <td align="center">1,48 (1,00&#8211;2,17), <italic>p</italic> = 0,048</td>
                <td align="center">1,46 (0,99&#8211;2,15), <italic>p</italic> = 0,053</td>
              </tr>
              <tr>
                <td>&#193;rea de superf&#237;cie corporal (m&#178;)</td>
                <td align="center">&#8212;</td>
                <td align="center">0,81 (0,34&#8211;1,92), <italic>p</italic> = 0,637</td>
                <td align="center">0,83 (0,35&#8211;1,98), <italic>p</italic> = 0,682</td>
              </tr>
              <tr>
                <td>PAS (mmHg)</td>
                <td align="center">&#8212;</td>
                <td align="center">&#8212;</td>
                <td align="center">1,01 (1,01&#8211;1,02), <italic>p</italic> &lt; 0,001</td>
              </tr>
              <tr>
                <td><italic>p</italic> (modelo global)</td>
                <td align="center">&lt; 0,001</td>
                <td align="center">&lt; 0,001</td>
                <td align="center">&lt; 0,001</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN2002">
              <p>LVOT VTI: integral velocidade&#8211;tempo do trato de sa&#237;da do ventr&#237;culo esquerdo; ASC: &#225;rea de superf&#237;cie corporal; PAS: press&#227;o arterial sist&#243;lica; HR: raz&#227;o de risco; IC: intervalo de confian&#231;a.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>Observou-se ainda correla&#231;&#227;o fraca entre LVOT VTI e altura (r = -0,073; p &lt; 0,001), e aus&#234;ncia de correla&#231;&#227;o significativa com peso (r = 0,039; p = 0,067) ou com &#225;rea de superf&#237;cie corporal (r = 0,0003; p = 0,99), refor&#231;ando a relativa independ&#234;ncia do LVOT VTI em rela&#231;&#227;o &#224;s caracter&#237;sticas antropom&#233;tricas.</p>
      <p>Em s&#237;ntese, uma LVOT VTI &lt; 15 cm foi associada a maior mortalidade em adultos residentes na comunidade em um pa&#237;s de renda m&#233;dia. A LVOT VTI pode representar uma m&#233;trica simples para rastreamento do desempenho card&#237;aco na estratifica&#231;&#227;o de risco cardiovascular em popula&#231;&#245;es gerais, independentemente de ajustes para vari&#225;veis demogr&#225;ficas e hemodin&#226;micas. Estudos adicionais s&#227;o necess&#225;rios para confirmar o papel independente da LVOT VTI na classifica&#231;&#227;o de risco e para definir pontos de corte clinicamente relevantes em diferentes contextos cl&#237;nicos.</p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <label>Vincula&#231;&#227;o Acad&#234;mica:</label>
          <p> N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
        </fn>
        <fn fn-type="other">
          <label>Aprova&#231;&#227;o &#201;tica e Consentimento Informado:</label>
          <p> Este estudo foi aprovado pelo Comit&#234; de &#201;tica do Hospital Cl&#237;nicas de Porto Alegre sob o n&#250;mero de protocolo 0017.1.069.000-06 194/06. Todos os procedimentos envolvidos nesse estudo est&#227;o de acordo com a Declara&#231;&#227;o de Helsinque de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#237;dos no estudo.</p>
        </fn>
        <fn fn-type="other">
          <label>Uso de Intelig&#234;ncia Artificial:</label>
          <p> Os autores n&#227;o utilizaram ferramentas de intelig&#234;ncia artificial no desenvolvimento deste trabalho.</p>
        </fn>
        <fn fn-type="data-availability" specific-use="data-available-upon-request">
          <label>Disponibilidade de Dados:</label>
          <p> Todo o conjunto de dados que d&#225; suporte aos resultados deste estudo est&#225; dispon&#237;vel mediante solicita&#231;&#227;o ao autor correspondente.</p>
        </fn>
        <fn fn-type="financial-disclosure">
          <label>Fontes de Financiamento:</label>
          <p> O presente estudo n&#227;o teve fontes de financiamento externas.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
